SecBot SecBot
6-K ·Filed Jun 1, 2026

DRTSW

Alpha Tau Medical Ltd.
BULLISH
Impact 7/10
Horizondays Processed5mo ago SEC0001213900-26-063182
Notable filing: 6-K
Actionable Insight ▲ Bullish

The strong survival and safety data is a significant catalyst for DRTSW. Expect short-term volatility as the market digests the ASCO presentation. Monitor upcoming IMPACT and ACAPELLA trial updates for further de-risking. The company may need to raise capital for larger trials, so watch for potential dilution.

DirectionBullish
Confidencehigh
Horizondays

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.02
T+0 close · Jun 1, 2026 · via day close
Latest settled
+281.37%
T+60 · $3.89
Vs SPY
+280.14%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 1 $1.02entry
  2. T+1 · 6mo ago 0.00%α −0.14% · $1.02
  3. T+5 · 5mo ago 0.00%α +2.75% · $1.02
  4. T+20 · 5mo ago +189.22%α +190.51% · $2.95
  5. T+60 · 3mo ago +281.37%α +280.14% · $3.89
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alpha Tau announced positive overall survival results from pooled Phase I/II Alpha DaRT pancreatic cancer studies at ASCO 2026. Median OS for second-line metastatic patients was 11.2 months vs historical ~4-6 months, with a favorable safety profile (no treatment-related deaths). The data de-risks the platform and supports advancement of the IMPACT trial.

Key Facts

  • Pooled analysis of three Phase I/II studies in locally advanced or metastatic PDAC.
  • Second-line metastatic mOS: 11.2 months from enrollment (historical ~4-6 months).
  • Second-line locally advanced mOS: 11.1 months from enrollment (historical ~9 months).
  • Third-line metastatic mOS: 7.9 months from enrollment (historical ~4-7 months).
  • Treatment-associated AEs in 36% of subjects, Grade ≥3 in 9%, no treatment-related deaths.
  • Data presented at 2026 ASCO Annual Meeting.

Financial Impact

Positive clinical data for a pre-revenue biotech; no financial figures disclosed.

Risk Factors

  • Early-stage, non-randomized data with small sample size.
  • Need for larger randomized trials to confirm efficacy.
  • Company is pre-revenue and may require additional financing.
  • Regulatory approval path uncertain.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-063182
Document: ea0292770-6k_alpha.htm0001213900-26-063182
Document: 0001213900-26-063182-index-headers.html0001213900-26-063182
Document: 0001213900-26-063182-index.html0001213900-26-063182
Document: 0001213900-26-063182.txt0001213900-26-063182

Track record

14 reports on DRTSW

Performance horizon

8 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +292.16% at T+60 after the Jun 3, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Jun 3, 202623w ago 6-K Bullish 7/10 Entry $1.02 to $4.00 ▲ +292.16% +289.66% vs SPY
  2. Jun 1, 202624w ago 6-K Bullish 7/10 Viewing Entry $1.02 to $3.89 ▲ +281.37% +280.14% vs SPY
  3. May 18, 202626w ago 6-K Neutral 5/10 Entry $1.02 to $3.89 ▲ +281.37% +275.08% vs SPY
  4. May 11, 202627w ago 6-K Bullish 7/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
  5. May 11, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
  6. May 8, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
  7. May 8, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
  8. May 7, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.58 ▲ +152.94% +149.11% vs SPY
  9. May 5, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.70 ▲ +164.71% +161.97% vs SPY
  10. May 4, 202628w ago 6-K Bullish 7/10 Entry $1.02 to $2.29 ▲ +124.51% +122.65% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 7h 48m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 1, 2026